Poor
Not Aligned
Patient Risk:
Low
Summary
Most clinical and dosing-related claims partially align with the provided FORTEO (teriparatide injection) label, but numerous included statements (especially pricing/access/discount programs and several common adverse effects, prescription/legal acquisition, and manufacturer/generic availability) are not supported by the provided prescribing information, resulting in poor overall label alignment.
Category Scores
Accurate Statements
Teriparatide is a parathyroid hormone analog.
Supported by 11 DESCRIPTION
Teriparatide is used to treat osteoporosis in postmenopausal women.
Supported by 1 INDICATIONS AND USAGE
Teriparatide is used to treat osteoporosis in men who are at high risk for fracture.
Supported by 1 INDICATIONS AND USAGE
Teriparatide stimulates bone formation.
Supported by 12 CLINICAL PHARMACOLOGY (Mechanism of Action)
Teriparatide reduces the risk of vertebral fractures.
Supported by 1 INDICATIONS AND USAGE
Teriparatide reduces the risk of non-vertebral fractures.
Supported by 1 INDICATIONS AND USAGE
The usual dose of teriparatide is 20 mcg administered subcutaneously once daily.
Supported by 2 DOSAGE AND ADMINISTRATION (2.1 Recommended Dosage)
Teriparatide is a bone-forming agent.
Supported by 12 CLINICAL PHARMACOLOGY (Mechanism of Action)
The originator brand of teriparatide is Forteo.
Supported by 11 DESCRIPTION
Unsupported Statements
The price of teriparatide injection for a three-month supply can vary significantly based on factors such as insurance coverage, pharmacy, and location.
Not supported/absent from the provided prescribing information.
A 3-month supply of teriparatide can range from approximately $4,000 to over $6,000.
Not supported/absent from the provided prescribing information.
The cost of teriparatide is influenced by the specific dosage required by the patient.
Not supported/absent from the provided prescribing information.
The cost of teriparatide is influenced by whether the purchase is brand name versus a generic version.
Not supported/absent from the provided prescribing information.
The cost of teriparatide is influenced by whether the purchase is made through a traditional pharmacy or a discount program.
Not supported/absent from the provided prescribing information.
Insurance plans can alter a patient's out-of-pocket expense through copays and deductibles.
Not supported/absent from the provided prescribing information.
Discount cards from pharmaceutical manufacturers or third-party providers can offer savings for teriparatide.
Not supported/absent from the provided prescribing information.
Comparing prices across different pharmacies, including online options, is advisable to reduce teriparatide cost.
Not supported/absent from the provided prescribing information.
Patient assistance programs offered by drug manufacturers can provide significant financial relief for eligible individuals receiving teriparatide.
Not supported/absent from the provided prescribing information.
Teriparatide increases bone mineral density.
Not supported/absent from the provided prescribing information sections.
Teriparatide commonly causes nausea.
Not supported/absent from the provided prescribing information sections.
Teriparatide commonly causes joint pain.
Not supported/absent from the provided prescribing information sections.
Teriparatide commonly causes leg cramps.
Not supported/absent from the provided prescribing information sections.
Teriparatide commonly causes dizziness.
Not supported/absent from the provided prescribing information sections.
Teriparatide is a prescription medication.
Not supported/absent from the provided prescribing information sections.
Teriparatide cannot be obtained without a valid prescription from a licensed healthcare provider.
Not supported/absent from the provided prescribing information sections.
Bisphosphonates are primarily antiresorptive agents.
Not supported/absent from the provided prescribing information sections.
Forteo is manufactured by Eli Lilly and Company.
Not supported/absent from the provided prescribing information sections.
Generic versions of teriparatide are also available.
Not supported/absent from the provided prescribing information sections.
Contradictions
Important Omissions
Boxed warnings, contraindications, and detailed warnings/precautions (beyond osteosarcoma) were not evaluated against the full label because the response did not address them.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported statements are primarily about cost/access and several adverse-effect and prescribing/legal-acquisition assertions; the response includes several correct efficacy and dosing elements, but label-unsupported adverse reaction 'common' claims could mislead expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple statements are not supported by the provided FDA label content (pricing/discount programs, several adverse reactions described as 'commonly', prescription/legal acquisition, and generic/manufacturer availability).
Suggested Improvement
Remove or qualify all price/access/discount/assistance program claims and any adverse reactions or legal-prescription statements that are not explicitly supported in the provided label text. Limit remaining claims to the label-supported indications, mechanism/bone formation language, dosing (20 mcg SC daily), and treatment-duration guidance (label-specific framing).